Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1638, Issue 1, 2003, Pages 1-19

  Goding, James W ^a   Grobben, Bert ^b   Slegers, Herman ^b  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Bone mineralization; Cell motility; Nucleotide pyrophosphatase; Purinergic receptor signalling; Type 2 diabetes

Indexed keywords

LYSOPHOSPHOLIPASE; METFORMIN; MONOCLONAL ANTIBODY; NUCLEOTIDE PYROPHOSPHATASE; PENTOXIFYLLINE; PHOSPHODIESTERASE;

AMINO TERMINAL SEQUENCE; BONE MINERALIZATION; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL INVASION; CELL LABELING; CELL MOTILITY; CELL POLARITY; CELL TYPE; CHEMICAL STRUCTURE; CHONDROCALCINOSIS; CRYSTAL; DATA BASE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; INSULIN RESISTANCE; JOINT CAPSULE; LIGAMENT; METASTASIS; MULTIGENE FAMILY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE CALCIFICATION;

EID: 0038664247     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(03)00058-9     Document Type: Review

References (202)

1. Bollen M., Gijsbers R., Ceulemans H., Stalmans W., Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit. Rev. Biochem. Mol. Biol. 35:2000;393-432.
2. Tokumura A., Majima E., Kariya Y., Tominaga K., Kogure K., Yasuda K., Fukuzawa K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277:2002;39436-39442.
3. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., Yamori T., Mills G.B., Inoue K., Aoki J., Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158:2002;227-233.
4. Banakh I., Sali A., Dubljevic V., Grobben B., Slegers H., Goding J.W. Structural basis of allotypes of ecto-nucleotide pyrophosphatase/phosphodiesterase (plasma cell membrane glycoprotein PC-1) in the mouse and rat, and analysis of allele-specific xenogeneic antibodies. Eur. J. Immunogenet. 29:2002;307-313.
5. Scott L.J., Delautier D., Meerson N.R., Trugnan G., Goding J.W., Maurice M. Biochemical and molecular identification of distinct forms of alkaline phosphodiesterase I expressed on the apical and basolateral plasma membrane surfaces of rat hepatocytes. Hepatology. 25:1997;995-1002.
6. Bello V., Goding J.W., Greengrass V., Sali A., Dubljevic V., Lenoir C., Trugnan G., Maurice M. Characterization of a di-leucine-based signal in the cytoplasmic tail of the nucleotide-pyrophosphatase NPP1 that mediates basolateral targeting but not endocytosis. Mol. Biol. Cell. 12:2001;3004-3015.
7. Kamikubo Y.I., Okumura Y., Loskutoff D.J. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. J. Biol. Chem. 277:2000;27109-27119.
8. Rebbe N.F., Hickman S. Modulation of nucleotide pyrophosphatase in plasmacytoma cells. Biochem. Biophys. Res. Commun. 175:1991;637-644.
9. Narita M., Goji J., Nakamura H., Sano K. Molecular cloning, expression, and localization of a brain-specific phosphodiesterase I/nucleotide pyrophosphatase (PD-Iα) from rat brain. J. Biol. Chem. 269:1994;28235-28242.
10. RB13-6 reveals relationship to human and murine PC-1. J. Biol. Chem. 270:1995;9849-9855.
11. Gijsbers R., Ceulemans H., Stalmans W., Bollen M. Structural and catalytic similarities between nucleotide pyrophosphatase/phosphodiesterase and alkaline phosphatases. J. Biol. Chem. 276:2001;1361-1368.
12. Andoh K., Piao J.H., Terashima K., Nakamura H., Sano K. Genomic structure and promoter analysis of the ecto-phosphodiesterase I gene (PDNP3) expressed in glial cells. Biochim. Biophys. Acta. 1446:1999;213-224.
13. Lee J., Jung I.D., Nam S.W., Clair T., Jeong E.M., Hong S.Y., Han J.W., Lee H.W., Stracke M.L., Lee H.Y. Enzymatic activation of autotaxin by divalent cations without EF-hand loop region involvement. Biochem. Pharmacol. 62:2001;219-224.
14. Uriarte M., Stalmans W., Hickman S., Bollen M. Phosphorylation and nucleotide-dependent dephosphorylation of hepatic polypeptides related to the plasma membrane differentiation antigen PC-1. Biochem. J. 293:1993;93-100.
15. Stefan C., Stalmans W., Bollen M. Threonine autophosphorylation and nucleotidylation of the hepatic membrane protein PC-1. Eur. J. Biochem. 241:1996;338-342.
16. Hosoda N., Hoshino S., Kanda Y., Katada T. Inhibition of phosphodiesterase/pyrophosphatase activity of PC-1 by its association with glycosaminoglycans. Eur. J. Biochem. 265:1999;763-770.
17. Oda Y., Kuo M.D., Huang S.S., Huang J.S. The major acidic fibroblast growth factor (aFGF)-stimulated phosphoprotein from bovine liver plasma membranes has aFGF-stimulated kinase, autoadenylation, and alkaline nucleotide phosphodiesterase activities. J. Biol. Chem. 268:1993;27318-27326.
18. Belli S.I., Mercuri F.A., Sali A., Goding J.W. Autophosphorylation of PC-1 (alkaline phosphodiesterase I/nucleotide pyrophosphatase) and analysis of the active site. Eur. J. Biochem. 228:1995;669-676.
19. Uriarte M., Stalmans W., Hickman S., Bollen M. Regulation of purified hepatic PC-1 (phosphodiesterase-I/nucleotide pyrophosphatase) by threonine auto(de)phosphorylation and by binding of acidic fibroblast growth factor. Biochem. J. 306:1995;271-277.
20. Clair T., Lee H.Y., Liotta L.A., Stracke M.L. Autotaxin is an ectoenzyme possessing 5′-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities. J. Biol. Chem. 272:1997;996-1001.
21. Belli S.I., van Driel I.R., Goding J.W. Identification and characterization of a soluble form of the plasma cell membrane glycoprotein PC-1 (5′-nucleotide phosphodiesterase). Eur. J. Biochem. 217:1993;421-428.
22. Meerson N.R., Bello V., Delaunay J.L., Slimane T.A., Delautier D., Lenoir C., Trugnan G., Maurice M. Intracellular traffic of the ecto-nucleotide pyrophosphatase/phosphodiesterase NPP3 to the apical plasma membrane of MDCK and Caco-2 cells: apical targeting occurs in the absence of N-glycosylation. J. Cell Sci. 113:2000;4193-4202.
23. Stracke M.L., Arestad A., Levine M., Krutzsch H.C., Liotta L.A. Autotaxin is an N-linked glycoprotein but the sugar moieties are not needed for its stimulation of cellular motility. Melanoma Res. 5:1995;203-209.
24. Stracke M.L., Krutzsch H.C., Unsworth E.J., Arestad A., Cioce V., Schiffmann E., Liotta L.A. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulation protein. J. Biol. Chem. 267:1992;2524-2529.
25. Murata J., Lee H.Y., Clair T., Krutzsch H.C., Arestad A., Sobel M.E., Liotta L.A., Stracke M.L. cDNA cloning of the human tumor motility-stimulating protein, Autotaxin, reveals homology with phosphodiesterases. J. Biol. Chem. 269:1994;30479-30484.
26. Meerson N.R., Delautier D., Durand-Schneider A.M., Moreau A., Schilsky M.L., Sternlieb I., Feldmann G., Maurice M. Identification of B10, an alkaline phosphodiesterase of the apical plasma membrane of hepatocytes and biliary cells, in rat serum: increased levels following bile duct ligation and during the development of cholangiocarcinoma. Hepatology. 27:1997;563-568.
27. Frittitta L., Camastra S., Baratta R., Costanzo B.V., D'Adamo M., Graci S., Spampinato D., Maddux B.A., Vigneri R., Ferrannini E., Trischitta V. A soluble PC-1 circulates in human plasma: relationship with insulin resistance and associated abnormalities. J. Clin. Endocrinol. Metab. 84:1999;3620-3625.
28. Harahap A.R., Goding J.W. Distribution of the murine plasma cell antigen PC-1 in non-lymphoid tissues. J. Immunol. 141:1988;2317-2320.
29. Johnson K., Hashimoto S., Lotz M., Pritzker K., Goding J., Terkeltaub R. Up-regulated expression of the phosphodiesterase nucleotide pyrophosphatase family member PC-1 is a marker and pathogenic factor for knee meniscal cartilage matrix calcification. Arthritis Rheum. 5:2001;1071-1081.
30. Blass-Kampmann S., Kindler-Röhrborn A., Deissler H., D'Urso D., Rajewsky M.F. In vitro differentiation of neural progenitor cells from prenatal rat brain: common cell surface glycoprotein on three glial cell subsets. J. Neurosci. Res. 48:1997;95-111.
31. Takahashi T., Old L.J., Boyse E.A. Surface alloantigens of plasma cells. J. Exp. Med. 131:1970;1325-1341.
32. Deterre P., Gelman L., Gary-Gouy H., Arrieumerlou C., Berthelier V., Tixier J.M., Ktorza S., Goding J., Schmitt C., Bismuth G. Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1. J. Immunol. 157:1996;1381-1388.
33. Yano T., Funakoshi I., Yamashina I. Purification and properties of nucleotide pyrophosphatase from human placenta. J. Biochem. 98:1985;1097-1107.
34. Yano T., Horie K., Kanamoto R., Kitagawa H., Funakoshi I., Yamashina I. Immunoaffinity purification and characterization of nucleotide pyrophosphatase from human placenta. Biochem. Biophys. Res. Commun. 147:1987;1061-1069.
35. Funakoshi I., Kato H., Horie K., Yano T., Hori Y., Kobayashi H., Inoue T., Suzuki H., Fukui S., Tsukahara M. Molecular cloning of cDNAs for human fibroblast nucleotide pyrophosphatase. Arch. Biochem. Biophys. 295:1992;180-187.
36. Huang R., Rosenbach M., Vaughn R., Provvedini D., Rebbe N., Hickman S., Goding J., Terkeltaub R. Expression of the murine plasma cell nucleotide pyrophosphohydrolase PC-1 is shared by human liver, bone, and cartilage cells. J. Clin. Invest. 94:1994;560-567.
37. Jin-Hua P., Goding J.W., Nakamura H., Sano K. Molecular cloning and chromosomal localization of PD-1beta (PNDP3), a new member of the human phosphodiesterase I genes. Genomics. 45:1997;412-415.
38. Grobben B., Anciaux K., Roymans D., Stefan C., Bollen M., Esmans E., Slegers H. An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. J. Neurochem. 72:1999;826-834.
39. Lee H.Y., Murata J., Clair T., Polymeropoulos M.H., Torres R., Manrow R.E., Liotta L.A., Stracke M.L. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem. Biophys. Res. Commun. 218:1996;714-719.
40. Fuss B., Baba H., Phan T., Tuohy V.K., Macklin W.B. Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function. J. Neurosci. 17:1997;9095-9103.
41. Bächner D., Ahrens M., Schroder D., Hoffmann A., Lauber J., Betat N., Steinert P., Flohe L., Gross G. Bmp-2 downstream targets in mesenchymal development identified by substractive cloning from recombinant mesenchymal progenitors (C3H10T1/2). Dev. Dyn. 213:1998;398-411.
42. Kawagoe H., Soma O., Goji J., Nishimura N., Narita M., Inazawa J., Nakamura H., Sano K. Molecular cloning and chromosomal assignment of the human brain-type phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2). Genomics. 30:1995;380-384.
43. Bühring H.J., Simmons P.J., Pudney M., Muller R., Jarrossay D., van Agthoven A., Willheim M., Brugger W., Valent P., Kanz L. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood. 94:1999;2343-2356.
44. Bühring H.J., Seiffert M., Giesert C., Marxer A., Kanz L., Valent P., Sano K. The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood. 97:2001;3303-3305.
45. Vollmayer P., Koch M., Braun N., Heine P., Servos J., Israr E., Kegel B., Zimmermann H. Multiple ecto-nucleotidases in PC12 cells: identification and cellular distribution after heterologous expression. J. Neurochem. 78:2001;1019-1028.
46. Buckley M.F., Loveland K.A., McKinstry W.J., Garson O.M., Goding J.W. Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. J. Biol. Chem. 265:1990;17506-17511.
47. Hilton M.J., Gutiérrez L., Zhang L., Moreno P.A., Reddy M., Brown N., Tan Y., Hill A., Wells D.E. An integrated physical map of 8q22-q24: use in positional cloning and deletion analysis of Langer-Giedion syndrome. Genomics. 71:2001;192-199.
48. Buckley M.F., Goding J.W. Plasma cell membrane glycoprotein gene Pca-1 (alkaline phosphodiesterase I) is linked to the proto-oncogene Myb on mouse chromosome 10. Immunogenetics. 36:1992;199-201.
49. Piao J.H., Matsuda Y., Nakamura H., Sano K. Assignment of Pdnp2, the gene encoding phosphodiesterase I/nucleotide pyrophosphatase 2, to mouse chromosome 15D2. Cytogenet. Cell Genet. 87:1999;172-174.
50. RB13-6 (Pdnpno) to rat chromosome band 1p12 by in situ hybridization. Cytogenet. Cell Genet. 73:1996;228.
51. Lotz M., Rosen F., McCabe G., Quach J., Blanco F., Dudler J., Solan J., Goding J., Seegmiller J.E., Terkeltaub R. Interleukin 1β suppresses transforming growth factor-induced inorganic pyrophosphate (PPi) production and expression of the PPi-generating enzyme PC-1 in human chondrocytes. Proc. Natl. Acad. Sci. U. S. A. 92:1994;10364-10368.
52. Solan J.L., Deftos L.J., Goding J.W., Terkeltaub R.A. Expression of the nucleoside triphosphate pyrophosphohydrolase PC-1 is induced by basic fibroblast growth factor (bFGF) and modulated by activation of the protein kinase A and C pathways in osteoblast-like osteosarcoma cells. J. Bone Miner. Res. 11:1996;183-192.
53. Bitzer M., von Gersdorff G., Liang D., Dominguez-Rosales A., Beg A.A., Rojkind M., Böttinger E.P. A mechanism of suppression of TGF-β/SMAD signaling by NF-kappa B/RelA. Genes Dev. 14:2000;187-197.
54. Verrecchia F., Tacheau C., Wagner E.F., Mauviel A. A central role for the Jun-N-terminal kinase pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven Smad-specific gene expression. J. Biol. Chem. 278:2002;1585-1593.
55. Bächer D., Ahrens M., Betat N., Schöder D., Gross G. Developmental expression analysis of murine autotaxin (ATX). Mech. Dev. 84:1999;121-125.
56. Cheon H., Yu S.J., Yoo D.H., Chae I.J., Song G.G., Sohn J. Increase expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-β1 in synovial fibroblasts from rheumatoid arthritis and normal individuals. Clin. Exp. Immunol. 127:2002;548-553.
57. Santos A.N., Riemann D., Santos A.N., Kehlen A., Thiele K., Langner J. Treatment of fibroblast-like synoviocytes with INF-γ results in the down-regulation of autotaxin mRNA. Biochem. Biophys. Res. Commun. 229:1996;419-424.
58. Kehlen A., Lauterbach R., Santos A.N., Thiele K., Kabisch U., Weber E., Riemann D., Langner J. IL-1beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 123:2001;147-154.
59. Ulloa L., Doody J., Massagué J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature. 397:1999;710-713.
60. Cohen P.S., Letterio J.J., Gaetano C., Chan J., Matsumoto K., Sporn M.B., Thiele C.J. Induction of transforming growth factor beta 1 and its receptors during all- trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res. 55:1995;2380-2386.
61. Dufner-Beattie J., Lemons R.S., Thorburn A. Retinoic acid-induced expression of autotaxin in N-Myc-amplified neuroblastoma cells. Mol. Carcinog. 30:2001;181-189.
62. Tice D.A., Szeto W., Soloviev I., Rubinfeld B., Fong S.E., Dugger D.L., Winer J., Williams P.M., Wieand D., Smith V., Schwall R.H., Pennica D., Polakis P. Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J. Biol. Chem. 277:2002;14329-14335.
63. Atfi A., Djelloul S., Chastre E., Davis R., Gespach C. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J. Biol. Chem. 272:1997;1429-1432.
64. Wolter S., Mushinski J.F., Saboori A.M., Resch K., Kracht M. Inducible expression of a constitutively active mutant of mitogen-activated protein kinase kinase 7 specifically activates c-JUN NH2-terminal protein kinase, alters expression of at least nine genes, and inhibits cell proliferation. J. Biol. Chem. 277:2002;3576-3584.
65. Kettenhofen R., Meyer zu Brickwedde M.K., Ko Y., Vetter H., Sachinidis A. Identification of a phosphodiesterase I/nucleotide pyrophosphatase-related gene mRNA in rat vascular smooth muscle cells by the differential display approach. J. Mol. Biol. 279:1998;323-329.
66. Kretzschmar M., Doody J., Timokhina I., Massagué J. A mechanism of repression of TGF-β/Smad signaling by oncogenic Ras. Genes Dev. 13:1999;804-816.
67. Voisin L., Foisy S., Giasson E., Lambert C., Moreau P., Meloche S. EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors. Am. J. Physiol., Cell Physiol. 283:2002;C446-C455.
68. Rachow J.W. Inorganic pyrophosphate metabolism in arthritis. Rheum. Dis. Clin. North Am. 14:1988;289-302.
69. Terkeltaub R.A. Inorganic pyrophosphate generation and disposition in pathophysiology. Am. J. Physiol. Cell Physiol. 281:2001;C1-C11.
70. Siegel S.A., Hummel C.F., Carty R.P. The role of nucleoside triphosphate pyrophosphohydrolase is in vitro nucleoside triphosphate-dependent matrix vesicle calcification. J. Biol. Chem. 258:1983;8601-8607.
71. Johnson K., Moffa A., Chen Y., Pritzker K., Goding J., Terkeltaub R. Matrix vesicle plasma cell membrane glycoprotein-1 regulates mineralization by murine osteoblastic MC3T3 cells. J. Bone Miner. Res. 14:1999;883-892.
72. Anderson H.C. Molecular biology of matrix vesicles. Clin. Orthop. 314:1995;266-280.
73. Ali S.Y. Matrix formation and mineralization in bone. Whitehead C.C. Bone Biology and Skeletal Disorders. 1992;19-38 Carfax/Abingdon, London.
74. Anderson H.C. Mechanisms of pathological calcification. Rheum. Dis. Clin. North Am. 14:1988;303-319.
75. Oyajobi B.O., Russell R.G., Caswell A.M. Modulation of ecto-nucleoside triphosphate pyrophosphatase activity of human osteoblast-like bone cells by 1 alpha, 25-dihydroxyvitamin D3, 24R, 25-dihydroxyvitamin D3, parathyroid hormone, and dexamethasone. J. Bone Miner. Res. 9:1994;1259-1266.
76. Johnson K., Vaingankar S., Chen Y., Moffa A., Goldring M.B., Sano K., Jin-Hua P., Sali A., Goding J., Terkeltaub R. Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes. Arthritis Rheum. 42:1999;1986-1997.
77. Ryan L.M., McCarty D.J. Understanding inorganic pyrophosphate metabolism: toward prevention of calcium pyrophosphatse dihydrate crystal deposition. Ann. Rheum. Dis. 54:1995;939-941.
78. Rosen F., McCabe G., Quach J., Solan J., Terkeltaub R., Seegmiller J.E., Lotz M. Differential effects of aging on human chondrocyte responses to transforming growth factor β Arthritis Rheum. 40:1997;1275-1281.
79. Masuda I., Hirose J. Animal models of pathological calcification. Curr. Opin. Rheumatol. 14:2002;287-291.
80. Rosenthal A.K., Cheung H.S., Ryan L.M. Transforming growth factor-β1 stimulates inorganic pyrophosphate elaboration by porcine cartilage. Arthritis Rheum. 34:1991;904-911.
81. 3. J. Biol. Chem. 269:1994;28374-28381.
82. Hessle L., Johnson K.A., Anderson H.C., Narisawa S., Sali A., Goding J.W., Terkeltaub R., Millan J.L. Tissue-non specific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc. Natl. Acad. Sci. U. S. A. 99:2002;9445-9449.
83. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet. 2:1988;706-709.
84. Pattrick M., Hamilton E., Hornby J., Doherty M. Synovial fluid pyrophosphate and nucleoside triphosphate pyrophosphatase: comparison between normal and diseased and between inflamed and non-inflamed joints. Ann. Rheum. Dis. 50:1991;214-218.
85. Tenenbauw J., Muniz O., Schumacher H.R., Good A.E., Howell D.S. Comparison of phosphohydrolase activities from articular cartilage in calcium pyrophosphate deposition disease and primary osteoarthritis. Arhritis Rheum. 24:1981;492-500.
86. Ryan L.M., Wortmann R.L., Karas B., Lynch M.P., McCarthy D.J. Pyrophosphohydrolase activity and inorganic pyrophosphate content of cultured human skin fibroblasts. J. Clin. Invest. 77:1986;1689-1693.
87. Wortmann R.L., Ryan L.M., Karas B., McCarthy D.J. Ecto-nucleoside triphosphate pyrophosphohydrolase activity and calcium pyrophosphate dihydrate crystal deposition disease. Adv. Exp. Med. Biol. 195:1986;153-156.
88. Rachow J.W., Ryan L.M., McCarty D.J., Halverson P.C. Synovial fluid inorganic pyrophosphate concentration and nucleotide pyrophosphohydrolase activity in basic calcium phosphate deposition arthropathy and Milwaukee shoulder syndrome. Arthritis Rheum. 31:1988;408-413.
89. Ryan L.M., Kurup I.V., Derfus B.A., Kushnaryov V.M. ATP-induced chondrocalcinosis. Arthritis Rheum. 35:1992;1520-1525.
90. Okawa A., Nakamura I., Goto S., Moriya H., Nakamura Y., Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat. Genet. 19:1998;271-273.
91. Sali A., Favarolo J.M., Terkeltaub R., Goding J.W. Germline deletion of the nucleoside triphosphate pyrophosphohydrolase (NTPPPH) plasma cell membrane glycoprotein (PC-1) produces abnormal calcification of peri-articular tissues. Vanduffel L., Lemmens R. Ecto-ATPases and Related Ectonucleotidases. 1999;267-282 Shaker Publishing, Maastricht, The Netherlands.
92. Terakado A., Tagawa M., Goto S., Yamazaki M., Moriya H., Fujimura S. Elevation of alkaline phosphatase activity induced by parathyroid hormone in osteoblast-like cells from the spinal hyperostotic mouse TWY (twy/twy). Calcif. Tissue Int. 56:1995;135-139.
93. Rutsch F., Vaingankar S., Johnson K., Goldfine I., Maddux B., Schauerte P., Kalhoff H., Sano K., Boisvert A., Superti-Furga A., Terkeltaub R. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in iodopathic infantile arterial calcification. Am. J. Pathol. 158:2001;543-554.
94. Tsuyama N. Ossification of the posterior longitudinal ligament of the spine. Clin. Orthop. 184:1984;71-84.
95. Nakamura I., Ikegawa S., Okawa S., Okuda S., Koshizuka Y., Kawaguchi H., Nakamura K., Koyama T., Goto S., Toguchida J., Matsushita M., Ochi T., Takaoka K., Nakamura Y. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum. Genet. 104:1999;492-497.
96. Yamazaki M., Moriya H., Goto S., Saitou Y., Arai K., Nagai Y. Increased type XI collagen expression in the spinal hyperostotic mouse (TWY/TWY). Calcif. Tissue Int. 48:1991;182-189.
97. Baba H., Furuswa N., Fukuda M., Maezawa Y., Imura S., Kawahara N., Nakahashi K., Tomita K. Potential role of streptozotocin in enhancing ossification of the posterior logitudinal ligament of the cervical spine in the hereditary spinal hyperostotic mouse (twy/twy). Eur. J. Histochem. 41:1997;191-202.
98. Ho A.M., Johnson M.D., Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 289:2000;265-270.
99. Pendleton A., Johnson M.D., Hughes A., Gurley K.A., Ho A.M., Doherty M., Dixey J., Gillet P., Loeuille D., McGrath R., Reginato A., Shiang R., Wright G., Netter P., Williams C., Kingsley D.M. Mutations in ANKH cause chondrocalcinosis. Am. J. Hum. Genet. 71:2002;933-940.
100. Terkeltaub R., Rosenbach M., Fong F., Goding J. Causal link between nucleotide pyrophosphatase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum. 37:1994;934-941.
101. Neary J.T., Norenberg M.D. Signaling by extracellular ATP: physiological and pathological considerations in neuronal-astrocytic interactions. Prog. Brain Res. 94:1992;145-151.
102. Burnstock G. Physiological and pathological roles of purines: an update. Drug Dev. Res. 28:1993;195-206.
103. Edwards F.A., Gibb A.J. ATP-a fast neurotransmitter. FEBS Lett. 325:1993;86-89.
104. Von Lubitz D.K.J.E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 365:1999;9-25.
105. Burnstock G., Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J. Pharmacol. Exp. Ther. 295:2000;862-869.
106. Latini S., Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem. 79:2001;463-484.
107. Ohkubo S., Kumazawa K., Sagawa K., Kimura J., Matsuoka I. Beta, gamma-methylene ATP-induced cAMP formation in C6Bu-1 cells: involvement of local metabolism and subsequent stimulation of adenosine A2B receptor. J. Neurochem. 76:2001;872-880.
108. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler. Thromb. Vasc. Biol. 22:2002;364-373.
109. Di Iorio P., Kleywegt S., Ciccarelli R., Traversa U., Andrew C.M., Crocker C.E., Werstiuk E.S., Rathbone M.P. Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia. 38:2002;179-190.
110. Schrier S.M., Florea B.I., Mulder G.I., Nagelkerke J.F., Ijzerman A.P. Apoptosis induced by extracellular ATP in mouse neuroblastoma cell line N1E-115: studies on involvement of P2 receptors and adenosine. Biochem. Pharmacol. 63:2002;1119-1126.
111. Anderson C.M., Parkinson F.E. Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides. Trends Pharmacol. Sci. 18:1997;387-392.
112. Harden K.T., Lazarowski E.R. Release of ATP and UTP from astrocytoma cells. Prog. Brain Res. 120:1999;135-143.
113. Lazarowski E.R., Boucher R.C., Harden K.T. Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J. Biol. Chem. 275:2000;31061-31068.
114. Bodin P., Burnstock G. Purinergic signalling: ATP release. Neurochem. Res. 26:2001;959-969.
115. Zimmermann H. Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog. Neurobiol. 49:1996;589-618.
116. Sneddon P., Westfall T.D., Todorov L.D., Mihaylova-Todorova S., Westfall D.P., Kennedy C. Modulation of purinergic neurotransmission. Prog. Brain Res. 120:1999;11-20.
117. Weisman G.A., Lustig K.D., Lane E., Huang N., Belzer I., Friedberg I. Growth inhibition of transformed mouse fibroblasts by adenosine occurs via generation of extracellular adenosine. J. Biol. Chem. 263:1988;12367-12372.
118. Abbrachio M.P., Saffrey M.J., Höpker V., Burnstock G. Modulation of astroglial cell proliferation by analogues of adenosine and ATP in primary cultures of rat striatum. Neuroscience. 59:1994;67-76.
119. 4 nucleotide receptors are involved in the regulation of rat aortic smooth muscle cells by UTP and ATP. Br. J. Pharmacol. 124:1998;703-710.
120. Seetulsingh-Goorah S.P., Steward B.W. Growth inhibition of HL-60 cells by extracellular ATP: concentration-dependent involvement of a P2 receptor and adenosine generation. Biochem. Biophys. Res. Commun. 250:1998;390-396.
121. - -receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen-activated protein kinase. Br. J. Pharmacol. 134:2001;402-408.
122. Fishman P., Baryehuda S.B., Vagman L. Adenosine and low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res. 58:1998;3181-3187.
123. Ohana G., Bar-Yehuda S., Barer F., Fishman P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J. Cell. Physiol. 186:2001;19-23.
124. Zimmermann H. Extracellular hydrolysis of ATP and other nucleotides. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;299-309.
125. Grobben B., Claes P., Roymans D., Esmans E.L., Van Onckelen H., Slegers H. Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists. Br. J. Pharmacol. 130:2000;139-145.
126. - receptor activate MAP kinase by a ras-independent pathway in rat C6 glioma. J. Neurochem. 78:2001;1325-1338.
127. North R.A., Surprenant A. Pharmacology of cloned P2X receptors. Annu. Rev. Pharmacol. Toxicol. 40:2000;563-580.
128. von Kügelgen I., Wetter A. Molecular pharmacology of P2Y-receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;310-323.
129. Redegeld F.A., Caldwell C.C., Sitkovsky M.V. Ecto-protein kinase: ecto-domain phosphorylation as a novel target for pharmacological manipulation? Trends Pharmacol. Sci. 20:1999;453-459.
130. Chow S.C., Kass G.E.N., Orrenius S. Purines and their role in apoptosis. Neuropharmacology. 36:1997;1149-1156.
131. Zhao Z., Kapoian T., Shepard M., Lianos E.A. Adenosine-induced apoptosis in glomerular mesangial cells. Kidney Int. 61:2002;1276-1285.
132. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol. Sci. 13:1992;439-445.
133. Che M., Gatmaitan Z., Arias I.M. Ectonucleotidases, purine nucleoside transporter, and function of the bile canalicular plasma membrane of the hepatocyte. FASEB J. 11:1997;101-108.
134. Chari R.S., Schutz S.M., Haebig J.E., Shimokura G.H., Cotton P.B., Fitz J.G., Meyers W.C. Adenosine nucleotides in bile. Am. J. Physiol. 270:1996;G246-G252.
135. Schlenker T., Romac J.M., Sharara A.I., Roman R.M., Kim S.J., LaRusso N., Liddle R.A., Fitz J.G. Regulation of bile secretion through apical purinergic receptors in cultured rat cholangiocytes. Am. J. Physiol. 273:1997;G1108-G1117.
136. Byrd J.C., Fearney F.J., Kim Y.S. Rat intestinal nucleotide-sugar pyrophosphatase. Localization, partial purification, and substrate specificity. J. Biol. Chem. 260:1985;7474-7480.
137. Zhang G., Zhao Z., Xu S., Ni L., Wang X. Expression of autotaxin mRNA in human hepatocelluar carcinoma. Chin. Med. J. 112:1999;330-332.
138. Kawagoe H., Stracke M.L., Nakamura H., Sano K. Expression and transcriptional regulation of the PD-Iα/autotaxin gene in neuroblastoma. Cancer Res. 57:1997;2516-2521.
139. Mulvaney P.T., Stracke M.L., Nam S.W., Woodhouse E., O'Keefe M., Clair T., Liotta L.A., Khaddurah-Daouk R., Schiffmann E. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase. Int. J. Cancer. 78:1998;46-52.
140. Yang Y., Mou L.J., Liu N., Tsao M.S. Autotaxin expression in non-small-cell lung cancer. Am. J. Respir. Cell Mol. Biol. 21:1999;216-222.
141. Lee H.Y., Clair T., Mulvaney P.T., Woodhouse E.C., Aznavoorian S., Liotta L.A., Stracke M.L. Stimulation of tumor motility linked to phosphodiesterase catalytic site of autotaxin. J. Biol. Chem. 271:1996;24408-24412.
142. Nam S.W., Clair T., Campo C.K., Lee H.Y., Liotta L.A., Stracke M.L. Autotaxin (ATX), a potent tumor mitogen, augments invasion and metastatic potential of ras-transformed cells. Oncogene. 19:2000;241-247.
143. Nam S.W., Clair T., Kim Y.S., McMarlin A., Schifmann E., Liotta L.A., Stracke M.L. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61:2001;6938-6944.
144. Saleh M., Davis I.D., Wilks A.F. The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium. Int. J. Cancer. 72:1997;664-672.
145. Volpert O.V., Fong T., Koch A.E., Peterson J.D., Waltenbaugh C., Tepper R.I., Bouck N.P. Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 188:1998;1039-1046.
146. Saleh M., Wiegmans A., Malone Q., Stylli S.S., Kaye A.H. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J. Natl. Cancer Inst. 91:1999;438-445.
147. Nobes C.D., Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J. Cell Biol. 144:1999;1235-1244.
148. Yart A., Roche S., Wetzker R., Laffargue M., Tonks N., Mayeux P., Chap H., Raynal P. A function for phosphoinositide 3-kinase β lipid products in coupling βγ to ras activation in response to lysophosphatidic acid. J. Biol. Chem. 277:2002;21167-21178.
149. Lee H.Y., Bae G.U., Jung I.D., Lee J.S., Kim Y.K., Noh S.H., Stracke M.L., Park C.G., Lee H.W., Han J.W. Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase γ in human melanoma cells. FEBS Lett. 515:2002;137-140.
150. RB13-6 induces fibroblasts and glioma cells to express astroglial proteins and invasive properties. FASEB J. 13:1999;657-666.
151. Durand-Schneider A.M., Maurice M., Dumont M., Feldman G. Effect of colchicine and phalloidin on the distribution of three plasma membrane antigens in rat hepatocytes: comparison with bile duct ligation. Hepatology. 7:1987;1239-1248.
152. Scoazec J.Y., Moreau A., Maurice M., Hassan N., Feldmann G. Detection of a biliary cell membrane glycoprotein in the serum of cholangiocarcinoma-bearing rats. Lab. Invest. 62:1990;459-466.
153. Maurice M., Schell M.J., Lardeux B., Hubbard A.L. Biosynthesis and intracellular transport of a bile canalicular plasma membrane protein: studies in vivo and in the perfused rat liver. Hepatology. 19:1994;648-655.
154. Garvey W.T., Birnbaum M.J. Cellular insulin action and insulin resistance. Bailliere's Clin. Endocrinol. Metab. 7:1993;785-873.
155. Krook A., O'Rahilly S. Mutant insulin receptors in syndromes of insulin resistance. Bailliere's Clin. Endocrinol. Metab. 10:1996;97-122.
156. Withers D.J., White M. Perspective: the insulin signaling sytem - a common link in the pathogenesis of type 2 diabetes. Endocrinology. 141:2000;1917-1921.
157. Le Roith D., Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. 24:2001;588-597.
158. Moller D.E., Flier J.S. Insulin resistance - mechanisms, syndromes, and implications. New Engl. J. Med. 325:1991;938-948.
159. Taylor S.I. Lilly lecture: molecular mechanisms of insulin resistance. Diabetes. 41:1992;1473-1490.
160. Maddux B.A., Sbraccia P., Reaven G.M., Moller D.E., Goldfine I.D. Inhibitors of insulin receptor tyrosine kinase in fibroblasts from diverse patients with impaired insulin action: evidence for a novel mechanism of postreceptor insulin resistance. J. Clin. Endocrinol. Metab. 77:1993;73-79.
161. Maddux B.A., Sbraccia P., Kumakura S., Sasson S., Youngren J., Fisher A., Spencer S., Grupe A., Henzel W., Steward T.A., Reaven G.M., Goldfine I.D. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature. 373:1995;448-451.
162. Whitehead J.P., Humphreys P.J., Dib K., Goding J.W., O'Rahilly S. Expression of the putative inhibitor of the insulin receptor tyrosine kinase PC-1 in dermal fibroblasts from patients with syndromes of severe insulin resistance. Clin. Endocrinol. 47:1997;65-70.
163. Belfiore A., Costantino A., Frasca F., Pandini G., Mineo R., Vigneri P., Maddux B., Goldfine I.D., Vigneri R. Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Mol. Endocrinol. 10:1996;1318-1326.
164. Pfeiffer A., Middelberg-Bisping K., Drewes C., Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care. 19:1996;1113-1117.
165. Reaven G. Role of insulin resistance in human disease. Diabetes. 35:1988;1595-1607.
166. Frittitta L., Youngren J., Vigneri R., Maddux B.A., Trischitta V., Goldfine I.D. PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia. 39:1996;1190-1195.
167. Frittitta L., Youngren J.F., Sbraccia P., Adamo M.D., Buongiorno A., Vigneri R., Goldfine I.D., Trischitta V. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-α gene expression, is associated with a reduction of the whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia. 40:1997;282-289.
168. Frittitta L., Spampinato D., Solini A., Nosadini R., Goldfine I.D., Vigneri R., Trischitta V. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes. 47:1998;1095-1100.
169. Youngren J.F., Maddux B.A., Sasson S., Sbraccia P., Tapscott E.B., Swanson M.S., Dohm G.L., Goldfine I.D. Skeletal muscle content of membrane glycoprotein PC-1 in obesity. Relationship to muscle glucose transport. Diabetes. 45:1996;1324-1328.
170. Pender C., Ortmeyer H.K., Hansen B.C., Goldfine I.D., Youngren J.F. Elevated plasma cell membrane glycoprotein levels and diminished insulin autophosphorylation in obese, insulin-resistant rhesus monkeys. Metabolism. 51:2002;465-470.
171. Shao J., Catalano P.M., Yamashita H., Ruyter I., Smith S., Youngren J., Friedman J.E. Decreased insulin receptor tyrosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus (GDM). Diabetes. 49:2000;603-610.
172. Tomazic M., Janez A., Sketelj A., Kocijancic A., Eckel J., Sharma P.M. Comparison of alterations in insulin signaling pathway in adipocytes from type II diabetic pregnant women and women with gestational diabetes mellitus. Diabetologia. 45:2002;502-508.
173. Stefanovic V., Antic S., Mitic-Zlatkovic M., Vlahovic P. Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin. Diabetes Metab. Res. Rev. 15:1999;400-404.
174. Li M., Youngren J.F., Manchem V.P., Kozlowski M., Zhang B.B., Maddux B.A., Goldfine I.D. Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells. Diabetes. 50:2001;2323-2328.
175. Pizzuti A., Frittitta L., Argiolas A., Baratta R., Goldfine I.D., Bozzali M., Ercolino T., Scarlato G., Iacoviello L., Vigneri R., Tassi V., Trischitta V. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 48:1999;1881-1884.
176. Gu H.F., Almgren P., Lindholm E., Frittitta L., Pizzuti A., Trischitta V., Groop L.C. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. Diabetes. 49:2000;1601-1603.
177. Rasmussen S.K., Urhammer S.A., Pizzuti A., Achwald S.M., Ekstrom C.T., Hansen L., Hansen T., Borch-Johansen K., Frittitta L., Trischitta V., Pedersen O. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. Diabetes. 49:2000;1608-1611.
178. De Cosmo S., Argiolas A., Miscio G., Thomas S., Piras G.P., Trevisan R., Perin P.C., Bacci S., Zucaro L., Margaglione M., Frittitta L., Pizzuti A., Tassi V., Viberti G.C., Trischitta V. A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria. Diabetes. 49:2000;521-524.
179. Tarnow L., Grarup N., Hansen T., Parving H.H., Pederson O. Diabetic microvasculature complications are not associated with two polymorphisms in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian type 1 diabetic patients. Nephrol. Dial. Transplant. 16:2001;1653-1656.
180. Jacobsen P., Grarup N., Tarnow L., Parving H.H., Pedersen O. PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. Nephrol. Dial. Transplant. 17:2002;1408-1412.
181. Canani L.H., Ng D.P., Smiles A., Rogus J.J., Warram J.H., Krolewski A.S. Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes. 51:2002;1188-1193.
182. Frittitta L., Ercolino T., Bozzali M., Argiolas A., Gravi S., Santagati M.G., Spampinato D., Di Paolo R., Cisternino C., Tassi V., Vigneri R., Pizzuti A., Trischitta V. A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes. 50:2001;1952-1955.
183. Duggirala R., Blangero J., Almasy L., Arya R., Dyer T.D., Williams K.L., Leach R.J., O'Connell P., Stern M.P. A major locus for fasting insulin concentrations and insulin resistance on chromosome 6q with strong pleiotropic effects on obesity-related phenotypes in nondiabetic Mexican Americans. Am. J. Hum. Genet. 68:2001;1149-1164.
184. Stefan C., Wera S., Stalmans W., Bollen M. The inhibition of the insulin receptor by the membrane protein PC-1 is not specific and results from the hydrolysis of ATP. Diabetes. 45:1996;980-983.
185. Özel B., Youngren J.F., Kim J.K., Goldfine I.D., Sung C.K., Youn J.H. The development of insulin resistance with high fat feeding in rats does not involve either decreased insulin receptor tyrosine kinase activity or membrane glycoprotein PC-1. Biochem. Mol. Med. 59:1996;174-181.
186. Youngren J.F., Paik J., Barnard R.J. Impaired insulin-receptor autophosphorylation is an early defect in fat-fed, insulin-resistant rats. J. Appl. Physiol. 91:2001;2240-2247.
187. Grupe A., Alleman J., Goldfine I.D., Sadick M., Stewart T.A. Inhibition of insulin receptor phosphorylation by PC-1 is not mediated by the hydrolysis of adenosine triphosphate or the generation of adenosine. J. Biol. Chem. 270:1995;22085-22088.
188. Hillaire-Buys D., Chapal J., Bertrand G., Petit P., Loubatieres-Mariani M.M. Purinergic receptors on insulin-secreting cells. Fundam. Clin. Pharmacol. 8:1994;117-127.
189. Heseltine L., Webster J.M., Taylor R. Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes. Mol. Cell. Biochem. 144:1995;147-151.
190. Maddux B.A., Goldfine I.D. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor α-subunit. Diabetes. 49:2000;13-19.
191. 121). Diabetes. 50:2001;831-836.
192. Marino-Buslje C., Mizuguchi K., Siddle K., Blundell T.L. A third fibronectin type III domain in the extracellular region of the insulin receptor family. FEBS Lett. 441:1998;331-336.
193. Sakoda H., Ogihara T., Anai M., Funaki M., Inukai K., Katagiri H., Fukushima Y., Onishi Y., Ono H., Yazaki Y., Kikuchi M., Oka Y., Asano T. No correlation of plasma cell 1 overexpression with insulin resistance in diabetic rats and 3T3-L1 adipocytes. Diabetes. 48:1999;1365-1371.
194. Kumakura S., Maddux B.A., Sung C.K. Overexpression of membrane glycoprotein PC-1 can influence insulin action at a post-receptor site. J. Cell. Biochem. 68:1998;366-377.
195. Saltiel A.R. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 104:2001;517-529.
196. Withers D.J., Gutierrez J.S., Towery H., Burks D.J., Ren J.M., Previs S., Zhang Y., Bernal D., Pons S., Shulman G.I., Bonner-Weir S., White M.F. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391:1998;900-904.
197. van Driel I.R., Goding J.W., Koch N. Plasma cell antigen PC-1 and the transferrin receptor in mouse, rat, and hamster: serologic and biochemical analysis. J. Immunol. 134:1985;3987-3993.
198. Oda Y., Kuo M.D., Huang S.S., Huang J.S. The plasma cell membrane glycoprotein, PC-1, is a threonine-specific protein kinase stimulated by acidic fibroblast growth factor. J. Biol. Chem. 266:1991;16791-16795.
199. Stefan C., Gijsbers R., Stalmans W., Bollen M. Differential regulation of the expression of nucleotide pyrophosphatase/phosphodiesterase in rat liver. Biochim. Biophys. Acta. 1450:1999;45-52.
200. Zimmermann H., Beaudoin A.R., Bollen M., Goding J.W., Guidotti G., Kirley T.L., Robson S.C., Sano K. Proposed nomenclature for two novel nucleotide hydrolyzing enzyme families expressed on the cell surface. Vanduffel L., Lemmens R. Ecto-ATPases and Related Ectonucleotidases. 2000;1-8 Shaker Publishing, Maastricht, The Netherlands.
201. Hirose J., Ryan L.M., Masuda I. Up-regulated expression of cartilage intermediate-layer protein and ANK in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum. 46:2002;3218-3229.
202. Roymans D., Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur. J. Biochem. 268:2001;487-498.